摘要
目的比较自体γδT细胞联合化疗与单纯化疗后非小细胞肺癌患者的临床疗效。方法 48例非小细胞肺癌患者随机分为对照组(单纯化疗组24例)和研究组(自体γδT细胞联合化疗组24例),对两组患者的客观缓解率、生活质量、免疫功能、3年生存情况及不良反应情况进行比较。结果研究组客观缓解率明显高于对照组(P<0.05);研究组卡氏评分明显高于对照组(P<0.05);两组患者治疗后CD3^+、CD8^+、CD56^+均显著高于治疗前(P<0.05);研究组3年生存率显著高于对照组(P<0.05);研究组患者治疗后骨髓抑制及恶心发生率明显低于对照组(P<0.05)。结论自体γδT细胞联合化疗能改善NSCLC患者生活质量,提高机体免疫功能,降低化疗的副作用。
Objective To compare the Therapeutic effect of autologous γδT cells combined with chemotherapy with chemotherapy alone in patients with non-small cell lung cancer. Methods A total of 48 cases of non-small cell lung cancer patients were randomly divided into control group （chemotherapy group 24 cases） and study group （autologous γδT cells combined with chemotherapy group 24 cases）. The objective response rate, the quality of life, immune function, the survival in 3 years and adverse reactions were compared. Results The objective response rate was significantly higher than the control group （ P 〈 0.05 ）. Karnofsky score of study group was significantly higher than the control group （ P 〈 0.05 ）. CD3^＋ , CD8^＋ and CD56^＋ were significantly higher after treatment than those of pretreatment （ P 〈 0.05 ）. The occurrence rates in patients with bone marrow suppression and nausea was significantly lower than that in the control group （ P 〈 0.05 ）. Conclusion Autologous γδT cells combined with chemotherapy can reduce chemotherapy side effects in patients with NSCLC and improve quality of life and immune function.
出处
《标记免疫分析与临床》
CAS
2016年第10期1177-1180,共4页
Labeled Immunoassays and Clinical Medicine
